Last reviewed · How we verify
Rebamipide and Esomeprazole
This combination product uses rebamipide to protect and promote gastric mucosa healing while esomeprazole reduces gastric acid secretion to treat acid-related disorders.
This combination product uses rebamipide to protect and promote gastric mucosa healing while esomeprazole reduces gastric acid secretion to treat acid-related disorders. Used for Gastric ulcer, Duodenal ulcer, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Rebamipide and Esomeprazole |
|---|---|
| Sponsor | Otsuka Pharmaceutical, Inc., Philippines |
| Drug class | Mucoprotective agent + Proton pump inhibitor combination |
| Target | Rebamipide: gastric mucosa protective mechanisms; Esomeprazole: H+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Rebamipide is a mucoprotective agent that enhances gastric mucus secretion, increases mucosal blood flow, and promotes healing of gastric lesions. Esomeprazole is a proton pump inhibitor that suppresses gastric acid production by blocking H+/K+-ATPase in parietal cells. Together, they provide dual protection and healing of the gastric mucosa in acid-peptic diseases.
Approved indications
- Gastric ulcer
- Duodenal ulcer
- Gastroesophageal reflux disease (GERD)
- Gastritis
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
- Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia (PHASE4)
- Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rebamipide and Esomeprazole CI brief — competitive landscape report
- Rebamipide and Esomeprazole updates RSS · CI watch RSS
- Otsuka Pharmaceutical, Inc., Philippines portfolio CI